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is further classified by tumor location; M1a tumors of
the upper thoracic esophagus metastasize to cervical
nodes and M1a tumors of the lower thoracic esophagus
metastasize to celiac lymph nodes (Table I).
This study evaluates the clinical relevance and treat-
ment implications of this new classification of distant
metastatic disease.
Patients and methods
From our prospective surgical database (patients undergo-
ing resection of esophageal carcinoma at The Cleveland
Clinic Foundation between January 1, 1983, and December
31, 1996) and our tumor registry (patients with esophageal
carcinoma treated at The Cleveland Clinic Foundation
between January 1, 1986, through December 31, 1996), 140
patients with M1 disease were identified. Patient age at pre-
sentation, sex, race, prior surgery, prior esophageal or gastric
surgery, use of endoscopic esophageal ultrasound (EUS),
histologic cell type, histologic differentiation, presence of
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Barrett’s mucosa, primary tumor site, and distant metastatic
status (M1a or M1b) were recorded. Therapies recorded
included surgery, chemotherapy and/or radiotherapy, and
local palliative therapy (stent or endoscopic lesion ablation).
Statistical methods. Descriptive statistics are summa-
rized as the mean and standard deviation for continuous
variables and as frequencies and percentages for categoric
variables. Continuous variables were compared between
patients with M1a and M1b tumors by means of the t test;
categoric variables were compared by means of the c 2 test.
The Kaplan-Meier method was used to estimate survival
and the log-rank test was used to compare survival
between patients with M1a and M1b disease. Cox propor-
tional hazards analysis was used to identify univariable
and multivariable correlates of survival. Two models of
survival were developed. In the first, the influence on sur-
vival of M1a versus M1b was simply adjusted for the con-
founding of surgery. In the second, stepwise analysis of
the variables described above (and in Table VI) were con-
sidered, except for cell type, because of low prevalence of
adenosquamous cancers. In addition, to assess the possible
influence of increased experience across time, the date of
diagnosis was evaluated. Variables were retained in the
model for P < .05.
Table I. Staging definitions
Site Definition
Primary
Upper thoracic esophagus Extends from the thoracic inlet to the tracheal carina, approximately 18 to 24 cm from the incisor teeth
Mid thoracic esophagus Extends from the tracheal carina to the inferior pulmonary vein, approximately 24 to 32 cm from the incisor teeth
Lower thoracic esophagus Extends from the inferior pulmonary vein to the esophagogastric junction including the intra-abdominal esophagus,
approximately 32 to 40 cm from the incisor teeth
Distant metastases
M1a Upper thoracic esophagus metastatic to cervical lymph nodes
Lower thoracic esophagus metastatic to celiac lymph nodes
M1b Upper thoracic esophagus metastatic to noncervical nonregional lymph nodes or other distant sites
Mid thoracic esophagus metastatic to either nonregional lymph nodes or other distant sites
Lower thoracic esophagus metastatic to nonceliac nonregional lymph nodes or other distant sites
Table II. Patient and carcinoma characteristics
All patients M1a M1b
Variable N % of 140 N % of 36 N % of 104 P
Male sex 115 82 34 94 81 78 .02
EUS 57 41 20 56 37 36 .04
Cell type .3
Adenocarcinoma 118 84 33 92 85 82
Squamous cell 18 13 2 6 16 15
Adenosquamous 4 3 1 3 3 3
Differentiation .6
Poor 82 59 19 53 63 61
Moderate-poor 11 8 4 11 7 7
Moderate 35 25 9 25 26 25
Moderate-well 6 4 3 8 3 3
Well 6 4 1 3 5 5
Barrett’s mucosa 32 23 9 25 23 22 .7
Primary site .2
Upper 2 1 0 0 2 2
Mid 7 5 0 0 7 7
Lower 131 94 36 100 95 91
EUS, Esophageal ultrasound.
Table III. Site of metastatic disease for 104 patients
with M1b disease 









Lung and liver 2 2
Liver and bone 2 2
Lung, liver, and bone 1 1




Patients. A total of 140 patients with esophageal car-
cinoma metastatic to distant sites were identified: 36
patients with M1a disease and 104 with M1b. Mean
age of the group was 62 ± 10 (SD) years (range 32-84
years) and was not different between patients with M1a
disease (mean 61 ± 10 years, range 44-83 years) and
those with M1b disease (mean 62 ± 10 years, range 32-
84 years) (P = .6). Descriptive characteristics are listed
in Table II. Sites of distant metastases for the M1b
group are listed in Table III. Multiple sites were rare,
occurring in only 5 patients, all of whom received non-
operative therapy.
Treatment. Forty-five patients were treated primari-
ly with surgery. Patients with M1a disease (n = 28)
were more likely to undergo surgery than patients with
M1b disease (n = 17) (78% vs 16%, P < .001). Of the
17 patients with M1b disease who were treated surgi-
cally, 9 underwent palliative resections, and 8 were
committed to resection before the M1b status was
determined. Chemotherapy and/or radiotherapy was
administered to 33 surgical patients, 22 with M1a dis-
ease (79%) and 11 with M1b disease (65%) (Table IV).
Nine of these received neoadjuvant therapy, 7 M1a and
2 M1b. In addition, 24 received postoperative adjuvant
therapy only, 15 M1a and 9 M1b.
Therapies for the 95 patients who did not undergo
surgery are listed in Table IV. Among these patients,
combined chemotherapy and radiotherapy was more
common in those with M1a disease (3/8, 38%) than in
those with M1b disease (9/87, 10%) (P = .03). It is this
specific difference in the nonsurgical group that
accounts for the overall difference in the pattern of ther-
apy between M1a and M1b (P = .04, Table IV). Local
therapy was administered to 55 patients (Table V).
Survival. Median length of follow-up (presentation
until death or last follow-up) was 6.4 months: 10.9
months (range 1.3-60 months) in the M1a group and
5.1 months (range 0.2-69 months) in the M1b group.
Five patients (3 M1a, 2 M1b) are currently alive.
Median and 5-year Kaplan-Meier survival estimates
are 11 months (95% CL 9-16 months) and 6% (95%
CL 0%-14%) for patients with M1a disease and 5
months (95% CL 4-7 months) and 2% (95% CL 0%-
5%) for those with M1b disease (P = .001) (Fig 1).
For M1a, surgical therapy afforded no clinically rele-
vant survival benefits (P = .2), although the curves
diverge at 12 months (Fig 2). Survival was similar for
Table IV. Chemotherapy and radiotherapy
Patients All patients M1a M1b P*
Surgical Therapy N % of 45 n % of 28 n % of 17 .5
Chemo/RT 13 29 9 32 4 24
Chemo only 2 4 2 7 0 0
RT only 18 40 11 39 7 41
None 12 27 6 21 6 35
Nonsurgical Therapy N % of 95 n % of 8 n % of 87 .13
Chemo/RT 12 13 3 38 9 10
Chemo only 20 21 2 25 18 21
RT only 31 33 1 12 30 34
None 32 34 2 25 30 34
All patients Therapy N % of 140 n % of 36 n % of 104 .04
Chemo/RT 25 18 12 33 13 12
Chemo only 22 16 4 11 18 17
RT only 49 35 12 33 37 36
None 44 31 8 22 36 35
Chemo, Chemotherapy; RT, radiotherapy.
*P for difference in pattern of therapies between M1a and M1b groups based on c 2 test.
Table V. Type of local therapy
All patients M1a M1b
Type n % of 140 n % of 36 n % of 104
Stent 9 6 1 3 8 8
Endoscopic 35 25 2 6 33 32
ablation
Both 11 8 2 6 9 9
None 85 61 31 86 54 52
P = .003 for difference in types of local therapy between M1a and M1b (c 2).
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surgical and nonsurgical therapy in the M1b group
(P = .6).
For patients receiving surgical therapy, pathologic T
status (pT) was not predictive of survival (P = .3). Only
3 patients did not have regional lymph node metastases
(N0), and therefore survival analysis was precluded.
For the 42 patients with regional lymph node metas-
tases (N1), the total number of positive nodes and per-
cent of nodes positive were not predictive of survival (P
= .7 and .4, respectively).
Univariable correlates of survival are listed in Table
VI. Two multivariable models are presented in Table
VII. In both, patients with M1b disease were at higher
risk than those with M1a disease. In the first model,
Fig 1. Survival from presentation to death or last follow-up in patients with M1a (solid line) or M1b (light line)
disease. The vertical bars represent 1 standard error of the survival estimates. The numbers in parentheses rep-
resent the number traced at 12, 24, and 36 months.
Fig 2. Survival from presentation to death or last follow-up in patients with M1a disease stratified by surgical
(solid line) versus nonsurgical (light line) therapy. The format is as in Fig 1.
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surgical therapy provided a survival benefit; however,
surgical therapy and M1a are confounded. A second
model shows that any chemotherapy and/or radiothera-
py offers a survival benefit regardless of M1 substage
or surgical therapy (Fig 3).
Discussion
Limitations. This study is a single-institution report
of a population that by definition is heterogeneous. All
patients undergoing surgery had a pathologic determi-
nation of stage. Those patients not receiving surgery
had a combination of clinical and pathologic staging.
Treatment of this varied group of patients was hetero-
geneous and included palliation alone, surgery,
chemotherapy and/or radiotherapy, or combinations of
these and surgery. This study did not include 4 patients
whose condition was clinically staged as M1a and
downstaged to M0 with chemotherapy and radiothera-
py and who then underwent surgery (Table VIII). Two
are alive without disease with a 50% survival at 13
months and beyond (95% CI 9%-91%). Despite these
limitations, useful conclusions can be drawn.
M1 subsets. Identification of nonregional lymph node
metastases as a separate staging subgroup has surgical
appeal. The progression of metastatic lymph node dis-
ease to a more distant site, still within surgical fields, has
prompted many to consider radical multiple field lym-
phadenectomy. However, its similarity to distant disease
(M1) was suggested by a comparable survival (5.5% at
5 years) in patients with both nonregional lymph node
metastases and other distant metastases.2 The presence
of distant metastatic disease, be it M1a or M1b, over-
whelms the importance of T and N and necessitates a
separate stage group. For carcinomas of the lower tho-
racic esophagus with celiac lymph node metastases, the
present study identifies a somewhat improved survival
for these patients (M1a) compared with those with other
distant metastases (M1b). However, this doubling of
median survival (5 months vs 11 months) and tripling of
5-year survival (2% vs 6%) is clinically unimportant
because the increased survival is consumed by the treat-
ment and recovery of the patient. This division of M1
staging has only anatomic merit and statistical signifi-
cance. To be of clinical significance, survival must
extend beyond the treatment and recovery phases.
Therapeutic implications. The present study has
therapeutic implications. There is a bias among sur-
geons to consider nonregional lymph node metastases
of esophageal carcinoma as an extension of regional
lymph node metastases (N1). Previously there have
been calls for classifying this entity as N2 disease, thus
implying that nonregional lymph node metastases are
Table VI. Univariable correlates of survival (Cox
models)
Variable/response HR 95% CI P
Sex
Female/male 1.2 0.8-1.8 .5
Age at presentation
Per 10-year increase 1.2 0.98-1.4 .08
Race
White/other 0.8 0.4-1.6 .6
Prior surgery
Yes/no 0.9 0.6-1.3 .6
Prior esophageal/gastric surgery
Yes/no 0.8 0.3-2.0 .7
Endoscopic ultrasound
Yes/no 0.9 0.6-1.2 .5
Cell type
SQ/AD 1.0 0.6-1.7 .98
AS/AD 3.3 1.2-9.1 .02
Barrett’s mucosa
Yes/no 0.9 0.6-1.4 .8
Metastatic disease group
M1b/M1a 1.9 1.3-2.8 .002
Type of therapy
Nonsurgical/surgical 1.7 1.2-2.4 .007
Any chemotherapy and/or 
radiotherapy
No/yes 2.3 1.6-3.4 < .001
Any chemotherapy
No/yes 2.0 1.4-2.9 < .001
Any radiation therapy
No/yes 1.4 0.96-1.9 .08
Local therapy (stent, endoscopic 
ablation, both)
Yes/no 1.3 0.9-1.8 .17
Year of presentation
Per 1-year increase 1.02 0.97-1.07 .5
AD, Adenocarcinoma; AS, adenosquamous; CI, confidence interval; HR, haz-
ard ratio; SQ, squamous cell. Note: Hazard ratios > 1 indicate a higher risk of
mortality.
Table VII. Risk factors for death
Variable/response HR 95% CI P
Model 1
Metastatic disease group
M1b/M1a 1.7 1.01-2.7 .04
Type of therapy
Nonsurgical/surgical 1.2 0.8-2.0 .3
Model 2*
Metastatic disease group
M1b/M1a 1.8 1.2-2.7 .004
Any chemotherapy and/or radiotherapy
No/yes 2.2 1.5-3.2 < .001
CI, Confidence interval; HR, hazard ratio.
*Nonsurgical versus surgical therapy with this model is associated with a P
value of .3.
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resectable.3,4 This is an important controversy, since
20% or more of surgical candidates with carcinoma of
the lower thoracic esophagus or carcinoma of the
esophagogastric junction will have celiac metastases.
In these patients, a 5-year survival of 15% has been
reported with resection and radical lymphadenecto-
my.3 In the present study, there is minimal difference
in survival of patients with M1a disease treated surgi-
cally versus those treated nonsurgically. However,
long-term survival is seen only in the rare patient
undergoing surgical therapy (8% ± 5% at 5 years).
This suggests that there are occasional patients with
M1a disease who will have long-term survival after
resection. Presently these patients cannot be identified
before resection and their survival may be independent
of surgery. Are we justified in subjecting the vast
majority of patients to ineffective morbid therapy for
the benefit of the occasional patient? Chemotherapy
and/or radiotherapy provides a survival advantage for
these patients regardless of M1 subgroup and should
be considered the standard against which further ther-
apies should be measured.
Conclusions
Metastases to nonregional lymph nodes and distant
sites are ominous findings in patients with esophageal
carcinoma. This study confirms the anatomic and statis-
tical significance of this subdivision of metastatic dis-
ease. However, this staging modification does not pro-
vide prognosticators within these groups that identify
improved survival and that can be used to direct therapy.
If a clinically important survival advantage for patients
with M1a disease is to be obtained, improvement of non-
surgical therapy is required. Surgery should be consid-
ered as an adjunct to this therapy and should be used
only in a protocol setting. Otherwise, surgery is the most
aggressive form of palliation but not the most effective.
We thank Diane Baisden for data collection and patient fol-
low-up and Lucinda Mitchin for manuscript preparation.
Fig 3. Survival from presentation to death or last follow-up in patients stratified without (solid line) or with (light
line) chemotherapy and/or radiotherapy. The format is as in Fig 1.
Table VIII. M1a patients whose conditions were downstaged to M0
Patient Cell type Pretreatment stage Pathologic stage Status Follow-up (months)
1 AD T3 N1 M1a T0 N0 M0 Alive, NED 79
2 AD T3 N1 M1a T3 N1 M0 Dead, M1b 4
3 AD T3 N1 M1a T1 N0 M0 Dead, NED 13
4 SQ T3 N1 M1a T0 N0 M0 Alive, NED 25
AD, Adenocarcinoma; NED, no evidence of disease; SQ, squamous cell carcinoma.
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Discussion
Dr Mark J. Krasna (Baltimore, Md). The rapidly increas-
ing incidence in esophageal cancer and the increased preva-
lence of Barrett’s esophagus make the discussion of staging
and treating esophageal cancer a highly pertinent one. This
year 12,000 Americans will be diagnosed with esophageal
cancer. More than 11,000 of these will be dead within 2
years, primarily from distant metastatic disease. If we could
identify subgroups of patients preoperatively, we could allo-
cate treatment options where the greatest benefit would result
with the least risk. 
This retrospective review of 140 patients from The
Cleveland Clinic identified 36 patients with M1a disease, that
is, metastasis to nonregional lymph nodes. Survival was only
5 months even in those with M1a disease. Clearly, treatment
philosophy changed during this trial. Why, for instance, did 7
patients with distant metastatic disease undergo surgical
resection? 
The authors point out that clinical staging was not done,
and the manuscript points out that the authors did not include
those patients whose malignant disease was downstaged with
chemotherapy or radiation therapy. Although Steup and asso-
ciates, from Belgium, reported a 17% 5-year survival in this
subset of patients, the current report showed poor overall sur-
vival. Our report by Ellis and colleagues showed a 28% to
38% 5-year survival with small lesions despite positive celi-
ac lymph nodes. Although the Walsh study showed poor sur-
vival with surgery alone, the recent intergroup study showed
a reasonable survival with surgery alone, including some
patients who also had thoracic esophageal lesions with posi-
tive celiac nodes. 
Rather than taking a nihilistic approach to this problem, we
would suggest the following algorithm. Nowadays celiac or
thoracic lymph nodes can easily be assessed with the aid of
modern staging techniques. We have shown a 94% accuracy
using laparoscopic lymph node staging in the past. Recently,
Reed and associates have published excellent staging results
with EUS-guided needle biopsies of celiac lymph nodes. If
lymph nodes are found to be positive, patients should be
enrolled in a study to see whether aggressive chemotherapy
and radiation therapy with or without surgery may offer any
advantage for survival. If results of such studies are negative,
these patients should be offered palliative care, whereas other
patients should be treated aggressively. In a recent phase II
study of 48 patients subjected to surgical staging and tri-
modality therapy, we reported a 66% complete pathologic
response in patients with negative celiac nodes and a 20%
complete pathologic response in those with positive celiac
nodes. Although this series is small, the implication is that
even in this subset of patients we can identify patients before
treatment who, with aggressive treatment, can get a signifi-
cant response. 
How would you treat an otherwise good-risk patient with
an adenocarcinoma of the distal esophagus who has a biopsy-
proven positive 1.5-cm celiac lymph node? Would you
endorse a change in the current classification to allow an N2
classification, rather than M1a, for this extent of disease?
Only with new staging techniques and large cooperative
treatment protocols will we effect a change in this new epi-
demic of esophageal cancer. 
Dr Christie. Thank you very much, Dr Krasna, for your
comments. To answer your first question, how to deal with a
patient who is a good surgical candidate and on preoperative
evaluation has evidence of celiac node metastases, M1a dis-
ease: We have 17 patients in this group who had preoperative
chemoradiation therapy. In 4 of the 17 patients, the disease
was downstaged from M1a to M0, and in that group of
patients, 3 had a complete pathologic response and 2 had a
very good clinical outcome. One patient had an incomplete
pathologic response. His disease was downstaged to M0 at
surgery but he ultimately died of M1b disease. This parallels
the results that you described with downstaging. Although the
numbers are small, this is a 20% downstaging with chemora-
diation. The approach to patients in whom preoperative eval-
uation discloses M1a disease should include chemotherapy or
chemoradiation therapy, with a consideration for the addition
of surgery, but the patient should be treated as part of a study
protocol. 
To answer your second question regarding whether the
staging should be changed to N2 disease, I do not think so.
Although survival is possible, survival parallels metastatic
disease to distant organs.
Dr Mark B. Orringer (Ann Arbor, Mich). This is an
important issue. Our current staging system for esophageal
cancer has some real deficiencies. The M1a/M1b designation
is one of them, and the T0 designation is another. If you now
give patients with large esophageal cancers and associated
adenopathy on computed tomographic scan chemotherapy
and radiation therapy, and they are complete responders with
no residual cancer in the resected specimen, they are consid-
ered to have T0 disease. But similarly, patients with intramu-
cosal carcinoma, which has one of the best prognoses, are
also considered to have T0 disease. We are lumping apples
and oranges into the T0 category, and that is not optimal. 
At the meeting of the American Surgical Association, we
presented our series of 1085 transhiatal resections. Eight hun-
dred of these resections were for cancer, and we virtually
have no survival at 5 years for patients with either stage IVA
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or stage IVB disease. Like Dr Christie, I think there may be a
small difference in stage IVA versus stage IVB. However, for
practical purposes, 90%-plus of these patients will be dead
within 5 years, most within 3 years. The question will come
up, if you are doing an esophagectomy and you find a 1-cm
nodule in the liver, shouldn’t you proceed with the
esophagectomy because, after all, that poor patient has dys-
phagia and needs palliation? Well, that poor patient will prob-
ably be dead within 6 months, and I have trouble subjecting
him or her to a major resection under those circumstances. 
What is a “celiac” node? If the involved node is right at the
origin of the left gastric artery from the celiac axis and it can
be resected with a specimen, we tend to designate it a “left
gastric node.” If the node is to the right of the celiac axis and
cannot be resected en bloc with the rest of the specimen, then
that becomes a “celiac node.” But is there really a survival
difference in patients who have such “central” nodal spread?
We have repeatedly found that when the nodes at the origin
of the left gastric artery near the celiac trunk are involved
with tumor, the survival is dismal. I guess I am in Mark
Krasna’s corner here. If you are the practicing surgeon and
you know preoperatively that the patient has celiac node dis-
ease, you should not be doing an esophageal resection unless
that patient has had some sort of a protocol attempt to elimi-
nate that adenopathy to provide better survival. Otherwise,
you are doing a palliative operation. Unless you can do it with
a mortality that is in the low single digits and get the patient
out of the hospital within a week, you have done more harm
than good. 
Dr Antoon E. M. R. Lerut (Leuven, Belgium). I would
like to congratulate you on this study because it emphasizes a
very difficult problem. 
Reasonable survival can be obtained with primary surgery.
Dr Krasna mentioned 17%. In our more recent experience,
with 2-field and 3-field extended lymphadenectomies, sur-
vival is more than 20% in advanced stage carcinoma. What
we learned from the operation is that indeed we are dealing
with a very bad clinical staging system. When you are doing
this kind of operation and you do a 3-field lymphadenectomy,
you will find 30% positive lymph nodes in the neck, and that
is where the problem arises. In that sort of situation we have
a mean of up to 9 positive lymph nodes, and that is the point
at which our clinical staging is failing, including the mini-
mally invasive thoracoscopic or laparoscopic staging. Also,
the echoendoscopists are failing. They tell me that when the
patient is in a flat position, a particular lymph node is seen on
the celiac axis, but when the patient is on the left side, the
same lymph node will be on the gastric artery. That makes a
difference between the N1 and M1a classifications. That is
another reason that we have so much difficulty in appreciat-
ing the results of induction chemotherapy. We simply do not
know what we are talking about because we do not have the
correct stage. Perhaps the positron emission tomographic
scan will help us in the future. However, my suggestion is
that there is indeed a place for an N2 classification rather than
M1. In this respect we have to measure tumor load, that is, the
number of positive lymph nodes, as was proposed 20 years
ago by Skinner. If there are fewer than 4 positive nodes (N1),
then primary surgery should yield a good 5-year survival. If
there are more positive lymph nodes (N2), then you probably
are failing, and I think that is the lesson. 
Dr Christie. We agree with that. Certainly there is evidence
that the number of lymph nodes may have a very important
effect on survival. The purpose of our study was to address the
relevance of the new change of the staging system.
Dr Carolyn E. Reed (Charleston, SC). I may be a bit con-
fused. I think this is a terribly important discussion because
adenocarcinoma of the distal esophagus and gastro-
esophageal junction is becoming increasingly prevalent. As
you know, metastasis to the left gastric/celiac axis is very
common. One of your coauthors, Dr Rice, has shown that
most of us see T3 tumors. With T3 tumors, there is more than
75% nodal involvement, and with distal adenocarcinomas,
the nodal involvement will be along the lesser curvature or
the celiac axis. 
Are you saying that if you have an adenocarcinoma of the
gastroesophageal junction at The Cleveland Clinic and if
EUS suggests that a celiac node is enlarged, you administer
chemotherapy and radiation therapy but no longer consider
the patient to be a surgical candidate? I also echo what other
people have said, that we need to try to prove up front
whether these are positive nodes before we make these judg-
ments. However, sometimes it is very difficult to say whether
a node is a proximal left gastric lymph node or a true celiac
axis lymph node. There are a few centimeters that can make
the difference. What is your new policy at The Cleveland
Clinic? 
Dr Christie. Dr Reed, I am no longer at The Cleveland
Clinic. Dr Rice may want to elaborate. 
Dr Rice. I would be happy to elaborate. We use EUS to
stage the disease in our patients. If the patient has large celi-
ac axis nodes, we are now using fine-needle aspiration. If that
patient has M1a disease demonstrated by fine-needle aspira-
tion, the prospect for survival is dismal. Surgery alone is not
offered to that patient. Instead, induction chemoradiation
therapy is offered with a resection on protocol. 
